Global COVID-19 treatment trial shows current antivirals are of little benefit to hospitalized patients

Interim results from the Solidarity Therapeutics Trial indicate that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.

Oct 16, 2020